ELIXIRON
Live / Applied — New application — not yet assigned to an examiner (as of 11 Sept 2026)
What this means for you
Not registered yet, but its 11 Sept 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 50102702
- Mark type
- Word mark
- Filed
- 11 Sept 2026
- Attorney of record
- Michael T. Smith
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of Alzheimer’s disease; Pharmaceutical preparations for the treatment of vitiligo; Pharmaceutical preparations for the treatment of hemophagocytic syndrome; Pharmaceutical preparations for the treatment of alopecia; Pharmaceutical preparations for the treatment of ALS (Amyotrophic Lateral Sclerosis); Pharmaceutical preparations for the treatment of Parkinson's disease; Pharmaceutical preparations for the treatment of neurodegenerative diseases; Pharmaceutical preparations for the treatment of immune diseases; Pharmaceutical preparations for the treatment of autoimmune diseases and disorders; Pharmaceutical preparations for the treatment of liver cancer; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for suppressing tumors
- Class 042 — Scientific and technological services: Scientific research in the field of immunology; Scientific research in the field of neurodegeneration; Conducting clinical trials for others; Clinical research services; Research and development of antibodies; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical reagents; Culturing of cells for others for scientific research purposes; Research and development of new products for others; Research and development of medicines; Technological research in the field of immunology; Scientific laboratory services; Scientific research; Technical consulting in the field of pharmaceutical studies; Technology consultation in the field of clinical research; Medical research in the field of antibodies; Technological research in the field of neurodegeneration
Owner
- ELIXIRON IMMUNOTHERAPEUTICS INC., Taipei City 115011, TW
Prosecution history
- 11 Sept 2026 — APPLICATION FILING RECEIPT MAILED
- 11 Sept 2026 — NEW APPLICATION ENTERED